Results 61 to 70 of about 9,833 (206)
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.ABSTRACT Vildagliptin (VDG) is a dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor used for type 2 diabetes (T2DM) treatment. Viewing to improve VDG treatment, a population pharmacokinetic (popPK) model was built to describe drug plasma, free liver and muscle concentrations determined by microdialysis in healthy and diabetic animals following 50 mg/kg i.v ...
Bruna Bernar Dias +2 more
wiley +1 more source
International Journal of Nanomedicine, 2019 Chen-Hung Lee,1 Ming-Jer Hsieh,1 Shang-Hung Chang,1 Kuo-Chun Hung,1 Chao-Jan Wang,2 Ming-Yi Hsu,2 Jyuhn-Huarng Juang,3 I-Chang Hsieh,1 Ming-Shien Wen,1 Shih-Jung Liu4,5 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial ...
Lee CH +9 more
doaj
Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients
Cancer Science, Volume 117, Issue 2, Page 468-475, February 2026.Treatment with DPP4 inhibitors was identified as a favorable prognostic factor in patients with advanced RCC. A more substantial degree of tumor shrinkage was observed in the subgroup of patients who received tyrosine kinase inhibitors or immune checkpoint inhibitors as first‐line therapy.
Shuhei Kamada +12 more
wiley +1 more source
Doentes com diagnóstico prévio de diabetes perdem menos peso após banda gástrica [PDF]
, 2010 [Resumo ...
Alves, Joaquim +12 more
core
The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3 [PDF]
, 2018 Aims To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs ...
Brito-Sanfiel, Miguel +7 more
core +4 more sources
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1191-1200, February 2026.Abstract Aim This study aimed to investigate the efficacy and safety of bi‐weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods This multicenter, open‐label, randomized controlled study assigned participants in a 1:1 ratio to either the ...
Congqing Pan +10 more
wiley +1 more source
Frontiers in Pharmacology, 2019 Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel anti-hyperglycemic drugs for type 2 diabetes. It has been reported that DDP-4 inhibitor could exert pleiotropic effects on cardiovascular system.
Yuqin Ji +10 more
doaj +1 more source
CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation† [PDF]
, 2017 OBJECTIVES The CD26 antigen is a transmembrane glycoprotein that is constitutively expressed on activated lymphocytes and in pulmonary parenchyma. This molecule is also identified as dipeptidyl peptidase-4 (DPP-4) that cleaves a host of biologically ...
Arni, Stephan +5 more
core
Diabeedi ravi ja kardiovaskulaarne risk [PDF]
, 2016 Eesti Arst 2016; 95(10):667 ...
Roosimaa, Mart
core +2 more sources